Hyperlipidemia Drugs Market by Product Type, Distribution Channel, End User 2024-2032
                     Global Hyperlipidemia 
Drugs Market Research 
and Forecast Report 
2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A cc o r d i ng  t o  t h e  l a t es t  r e p o r t  b y  I M A R C  G r o up ,  t i t l e d  " H y p e r l i p id e m ia  D r u g s  Ma r k e t :  
G l o b a l  I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  Gr o w th ,  O p p o r t u n i t y  a n d  F o r e c as t  2 0 2 4 -
20 3 2 , "  t h e  g l o b a l  h y p e r l i p i d e m i a  d r u g s  m a r ke t  s i z e  r e a c he d  U S $  2 2 . 7  B i l l i o n  i n  2 0 2 3 .
H yp e r l i p i d em i a  r e f e r s  t o  a  c o n d i t i o n  t ha t  c a u se s  a b n o r m a l l y  h i gh  l e v e l s  o f  f a t s  o r  l i p i d s  
i n  t h e  b l o o d .  I t  i s  a  co m m on  t yp e  o f  d y s l i p i d e m i a  t h a t  c a n  b e  i n h e r i t ed  o r  re s u l t  f r o m  a n  
Report un h e a l t h y  l i f e s t y l e  an d  p o o r  d i e t .  T h e  d i so r d e r  ma y  l e a d  to  c a r d i a c  s t r o k e ,  p e r i p h e ra l  
va s c u l a r  d i s e as e s ,  o b e s i t y ,  h y p e r t e n s i o n ,  an d  ca r d i o v as c u l a r  d i s o r d e r s ( C V D s ) .  
H yp e r l i p i d em i a  c a n  b e  d e t e c t ed  b y  p e r f o r m i n g  a  b l o o d  t es t  c a l l e d  a  l i p i d  p a n e l  o r  l i p i d  
Highlight and p r o f i l e .  
S ta t i n s  a re  t h e  p r i ma r y  l i ne  o f  t r e a t m en t  i n  s e c on d a r y  hy p e r l i p i de m i a  c a u s e d  b y  a n  
Description un h e a l t h y  l i f e s t y l e .  S o m e  o f  t he  o t h e r  c o mm o n  d r u g s  u s e d  i n  t h e  t r e a t me n t  o f  hy p e r l i p i de m i a  a re  b i l e  a c i d  s e qu e s t ra n t s ,  P C S K 9 ,  a n d  m i sc e l l a n eo u s  
an t i h y p e r l i p i d e m i c  a g e n ts ,  w h i ch  h e l p  re d u c e  t h e  p r od u c t i o n  o f  c ho l e s t e ro l  i n  t he  l i v e r .  
T he y  a l s o  l o w e r  t h e  n u mb e r  o f  l i p i d s  i n  t h e  b l o o d s t r e a m  a nd  r e d u c e  i n f l a m ma t i o n  a n d  
da m a g e  d o n e  t o  t h e  c e l l s .
R eq u e s t  f o r  a  P D F  sa m p le  o f  th i s  r ep o r t :  
h t t p s : / /w w w . i ma r c g r o u p . co m / h yp e r l i p i de m i a - d r u g s - ma r k e t / r e q u es t s a mp l e
Report Description
Global  Hyper l ip idemia Drugs Market  Trends:
The g loba l  hyper l ip idemia  drugs marke t  is  pr imar i ly  dr i ven by  the inc reas ing awareness regard ing the  
assoc ia ted r i sks  o f  CVDs and h igh  cho les tero l .  Governments  a re  in t roduc ing new gu ide l ines rede f in ing a t - r i sk  
pa t ient  g roups and recommend ing the  use  o f  an t i -hyper l ip idemics  to  lower  the  r i sk  o f  these  d iseases .  In  
add i t ion  to  th is ,  the  upcoming pa tent  exp i ra t ion  has resu l ted in  the  gener ic iza t ion o f  s ta t in  and  cho les te ro l  
absorpt ion inh ib i to rs ,  wh ich  i s  s ign i f i cant ly  augment ing the marke t  growth.  
Fur thermore ,  the  launch  o f  innovat ive  products ,  such  as  the  deve lopment  o f  nove l  d rugs ,  wh ich o f fe r  improved  
e f f icacy and  safe ty  p ro f i le ,  is  pos i t i ve ly  impac t ing the  marke t  across  the  g lobe .  Moreover ,  there  has been 
ex tens ive  research  and  deve lopment  (R&D)  ac t iv i t ies  fo r  deve lop ing  innovat ive  drugs.
Looking forward ,  the market  is  ant ic ipated  to  reach a  va lue  of  US$ 26 .8  Bi l l ion  by 2032,  exhib i t ing a  
CAGR of  1 .8% dur ing  2024-2032.
View Report  TOC,  F igures and Tables :  h t tps: / /www. imarcgroup.com/hyper l ip idemia-drugs-market
Breakup by Drug Type:
• Statins
• Bi le Acid Sequestrants
• Cholesterol  Absorption Inhibitors
• PCSK9 Inhibitors
Report • Others
Segmentation Breakup by End User:
• Hospitals
• Clinics
• Others
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
Report • Middle East and Afr ica
Segmentation
• Amgen Inc.
• AstraZeneca PLC
• Dai ichi Sankyo Company Limited
•
Competitive El i  Li l ly and Company
• Esperion Therapeutics Inc.
Landscape • GlaxoSmithKl ine Pharmaceuticals Limited 
with Key (GlaxoSmithKl ine Plc)
• Immuron Limited
Players • Ionis Pharmaceuticals Inc.
• Merck & Co. Inc.
• Pfi zer Inc.
• Sanofi  S.A.
What was the size of the global hyperlipidemia 
drugs market in 2023?
What is the expected growth rate of the global 
hyperlipidemia drugs market during 2024-2032?
What are the key factors driving the global 
Key hyperlipidemia drugs market?
Questions What has been the impact of COVID-19 on the 
global hyperlipidemia drugs market?
Answered in 
What is the breakup of the global hyperlipidemia 
the Report drugs market based on the drug type?
What is the breakup of the global hyperlipidemia 
drugs market based on the end user?
What are the key regions in the global 
hyperlipidemia drugs market?
Who are the key players/companies in the global 
hyperlipidemia drugs market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  H y p e r l i p i d e m i a  D r u g s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  D r u g  T y p e
    6 . 1     S t a t i n s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     B i l e  A c i d  S e q u e s t r a n t s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     C h o l e s t e r o l  A b s o r p t i o n  I n h i b i t o r s
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
    6 . 4     P C S K 9  I n h i b i t o r s
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
    6 . 5     O t h e r s
        6 . 5 . 1  M a r k e t  T r e n d s
        6 . 5 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  E n d  U s e r
    7 . 1     H o s p i t a l s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
Table of     7 . 2     C l i n i c s        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     O t h e r s
Contents         7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  R e g i o n
    8 . 1     N o r t h  A m e r i c a
        8 . 1 . 1  U n i t e d  S t a t e s
           8 . 1 . 1 . 1  M a r k e t  T r e n d s
           8 . 1 . 1 . 2  M a r k e t  F o r e c a s t
        8 . 1 . 2  C a n a d a
           8 . 1 . 2 . 1  M a r k e t  T r e n d s
           8 . 1 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 2     A s i a  P a c i f i c
        8 . 2 . 1  C h i n a
           8 . 2 . 1 . 1  M a r k e t  T r e n d s
           8 . 2 . 1 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /h yp e r l i p i d em ia -d rugs -m a rke t / t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]